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Ready for Prime-Time Use as Surrogates
of Subclinical Myocardial Injury?
We read with great interest the recent paper by Rubin et al. (1) on
he association of hyperglycemia with subclinical myocardial injury,
ndicated by the correlation between glycated hemoglobin (HbA1c)
and high-sensitivity cardiac troponin T (hs-cTnT), respectively.
As pointed out by the authors (1), HbA1c, in addition to being
n established marker for the monitoring of medium-term glyce-
ic status, it is now also recommended for the screening and
iagnosis of diabetes mellitus (HbA1c 6.5%) (2). However, it
should be stressed that only certain standardized HbA1c assays are
uitable for diagnostic purposes and definitely none of the point-
f-care ones, as stressed by the American Diabetes Association (2).
The introduction of the novel hs-cTnT assays, developed to
rovide a more sensitive and timely diagnosis or rule-out of acute
oronary syndromes, has rendered clinicians and scientists eager
or their use in daily practice and in clinical research as surrogates
or several endpoints. However, before starting to use them to
ump to clinically relevant conclusions, we need to clarify what a
inor elevation of hs-cTnT level truly stands for, especially given
he fact that the applied cutoffs have been derived by fairly healthy
nd relatively young populations. On this issue, the authors are to
e congratulated because they seem to have made every effort to
djust for several variables and potential confounders (1). How-
ver, they also excluded individuals with advanced age or comor-
idities, such as atrial fibrillation, renal dysfunction, and stroke,
nd therefore their findings may not be applicable to the general
opulation.
The pathophysiology underlying the minor troponin increase
nd the impact of several parameters that may impair its release or
learance and therefore the values detected by the highly sensitive
ssays should be refined (3). The establishment of different age-,
ex-, or medical history–specific cutoffs seems quite complicated,
hereas some authors have developed algorithms to guide the
linical use of hs-cTnT in different patient groups. On the other
and, the clinical benefit and the cost-effectiveness of modifying
ur therapeutic strategies according to the results of hs-cTnT tests
hould also be evaluated by proper trials.
The high sensitivity of the new troponin assays enhances their
linical performance but also increases the need for better refine-
ent of their clinical significance.
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Is Glycated Hemoglobin an
Accurate Enough Predictor of
Subclinical Myocardial Injury or
a Simple Precursor of Advanced
Glycation End Products?
We read with interest the elegantly written paper by Rubin et al.
(1) relating to the analysis of the association between categories of
glycated hemoglobin (HbA1c) and high-sensitivity cardiac tro-
onin T (hs-cTnT) in participants without coronary heart disease
CHD) in the ARIC (Atherosclerosis Risk in Communities)
tudy. In a community-based population of almost 10,000 subjects
ithout clinically evident CHD, chronic hyperglycemia was indepen-
ently associated with subclinical myocardial injury, as assessed by
levated levels of hs-cTnT in both persons with and without diabetes.
We congratulate the authors for this research. However, we
ave some major concerns regarding the explanation that the
uthors find for this relationship. In particular, although the
uthors already refer in the discussion that advanced glycation
ndproducts (AGEs) may play an important role in the association
etween HbA1c and hs-cTnT, we would like to emphasize this
nteraction. Interestingly, within the DCCT study (2), AGE levels
ere a better predictor of progression to complications than
bA1c, with more than one third of the variance in complications
ttributed to differences in AGE indices. The influence of AGE
evels was even more evident in the intensive glycemic control
ohort, suggesting that, although glycemic control is important, it
s not sufficient to prevent progressive complications.
AGEs are molecules that appear in plasma and tissues and are
enerated nonenzymatically by glycation and oxidation of proteins
s a consequence of the Maillard reaction, which is driven by
xidative stress in its final step. Arteriosclerosis and diastolic
ysfunction are more prevalent in both diabetic patients and those
